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Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase 
inhibition   
Catherine L. Tookea,c, Philip Hinchliffea, Alen Krajncb, Adrian J. Mulhollandc, Jürgen Bremb, 
Christopher J. Schofieldb, James Spencera,* 
Klebsiella pneumoniae carbapenemase-2 (KPC-2) is a serine-β-lactamase (SBL) capable of hydrolysing almost 
all β-lactam antibiotics. We compare KPC-2 inhibition by vaborbactam, a clinically-approved monocyclic 
boronate, and VNRX-5133 (taniborbactam), a bicyclic boronate in late-stage clinical development. 
Vaborbactam inhibition is slowly reversible, whereas taniborbactam has an off-rate indicating essentially 
irreversible complex formation and a 15-fold higher on-rate, although both potentiate β-lactam activity against 
KPC-2-expressing K. pneumoniae. High resolution X-ray crystal structures reveal closely related binding modes 
for both inhibitors to KPC-2, with differences apparent only in positioning of the endocyclic boronate ester 
oxygen. The results indicate the bicyclic boronate scaffold as both an efficient, long-lasting, KPC-2 inhibitor and 
capable of supporting further iterations that may improve potency against specific enzyme targets and 
pre-empt the emergence of inhibitor resistant KPC-2 variants.
Introduction 
β-Lactamase production by Gram-negative bacteria (GNB) such as 
Klebsiella pneumoniae, Pseudomonas aeruginosa and Escherichia 
coli (organisms that are important causes of healthcare-associated 
infections)1 is a major antibiotic resistance mechanism. 
β-Lactamases are divided into four classes; classes A, C and D use a 
nucleophilic serine to hydrolyse β-lactam antibiotics, while class B 
enzymes employ zinc ions in their active site.2 Of particular clinical 
importance is the widely disseminated, plasmid-encoded Klebsiella 
pneumoniae carbapenemase-2 (KPC-2), a class A serine-β-lactamase 
(SBL).3 The wide spectrum of KPC-2 activity extends to late-
generation cephalosporins as well as the last-resort carbapenems 
such as meropenem.4 Antibiotic hydrolysis by SBLs, like KPC-2, 
occurs through attack on the β-lactam ring by the nucleophilic 
serine to form an acyl-enzyme complex via a tetrahedral (sp3 
hybridized) intermediate (Figure 1A), followed by subsequent 
deacylation to release the inactive hydrolysed product.  
The combination of a β-lactam antibiotic with a β-lactamase 
inhibitor is a clinically validated route to overcoming resistance.5 For 
example, avibactam, a recent clinical introduction, is a non-β-
lactam-based diazabicyclooctane (DBO) inhibitor used in 
combination with the third-generation cephalosporin ceftazidime  
Figure 1. β-Lactam hydrolysis by serine-β-lactamases and cyclic boronate 
inhibitor structures. (A) Outline mechanism for acyl-enzyme formation 
during β-lactam hydrolysis by SBLs. The common tetrahedral ‘core’ is in 
green. (B) Vaborbactam forms a covalent bond to the nucleophilic serine in 
SBLs, with the sp3 formed boronate mimicking the common tetrahedral 
intermediate in A. The carbon atoms of the cyclic boronate core are 
numbered. (C) Formation of the tetrahedral form of taniborbactam (sp3 
hybridized boron) on interaction with SBLs.  
 
 
(Avycaz®) for treatment of complicated urinary tract infections 
(UTIs) and intra-abdominal infections (IAIs).6 Mechanistically, 
avibactam forms a reversible, covalent, carbamoyl ester linkage to 
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the nucleophilic serine of SBLs after ring opening.7 Further iterations 
of the avibactam core are in development, with relebactam recently 
approved for the treatment of complicated UTIs and IAIs.8 However, 
DBOs have variable activity, are not active against MBLs,9 and there 
is evidence now emerging that SBLs (particularly KPC-2) can evolve 
to resist the action of the DBO combination Avycaz®.10 In addition, 
some MBLs are known to hydrolyse avibactam, thus highlighting the 
possibility that MBL production by GNB could contribute to DBO 
resistance.9 There is therefore continued interest in developing 
additional classes of non-β-lactam based SBL and MBL inhibitors.11 
Boronate-based compounds have long been known as β-lactamase 
inhibitors.11-16 In 2017 the combination of vaborbactam (a 
monocyclic boronate, Figure 1B) with meropenem (Vabomere®) was 
clinically approved to treat complicated UTIs.5, 17 Vaborbactam is 
particularly potent against the SBL KPC-2, but is not active against 
class D SBLs,18 and only moderately inhibits some MBLs.18 Further 
development of cyclic boronates has led to compounds containing 
bicyclic, rather than monocyclic cores.11, 19, 20 Bicyclic boronates 
were shown to inhibit the majority of tested SBLs from all classes, 
including KPC-2, and some MBLs.19, 20 Taniborbactam (Figure 1C, 
originally named VNRX-5133), is one such iteration, now in Phase 3 
clinical trials in combination with cefepime.21 Both mono- and bi-
cyclic boronates act as covalent inhibitors, with the mechanism of 
inhibition involving formation of a sp3 hybridized boron covalently 
bound to the nucleophilic serine, mimicking the tetrahedral 
intermediate formed during SBL/MBL catalysis19-21 (Figure 1). The 
sp2 hybridised form of boron-based inhibitors  has been proposed 
to mimic the intact β-lactam, facilitating rapid binding to the active 
site.19-21 Moreover, in crystallographic analyses of the subclass B1 
MBL New Delhi β-lactamase-1 (NDM-1) in complex with 
taniborbactam, an unexpected cyclization of the acylamino oxygen 
onto the boron of the bicyclic core to give a tricyclic form21 
highlighted the ability of boron-based inhibitors to interchange 
between different forms. 
We compare KPC-2 inhibition by vaborbactam and 
taniborbactam, representatives of clinically relevant mono- and 
bicyclic boronates, respectively. The kinetic, microbiological and 
structural data provided describe the mechanism of KPC inhibition 
by both compounds and inform on future iterations of cyclic 
boronates which may retain or enhance activity against this 
clinically important SBL and its growing array of variants. 
 
Results and discussion 
 
Kinetics and Microbiology 
Cyclic boronates (including vaborbactam and bicyclic analogues of 
taniborbactam) have previously been shown to exhibit nanomolar 
IC50 values against some class A β-lactamases, including KPC-2.18 
However, to elucidate the inhibition profiles of these two related 
compounds, detailed kinetic comparisons are required. Accordingly, 
we directly compared the kinetics of in vitro KPC-2 inhibition by the 
clinically relevant vaborbactam and taniborbactam (Table 1, Figure 
S1). While both inhibitors exhibit similar IC50s (35/37 nM after 10 
min pre-incubation), they differ substantially under more detailed 
kinetic analysis. Compared to vaborbactam, taniborbactam exhibits 
a lower Kiapp (calculated with no pre-incubation, 1.3 vs 8.5 µM) and 
an increased (15-fold higher) on-rate (k2/K, Figure S1).  
Table 1. Kinetic parameters for KPC-2 inhibition. 
Inhibitor 
IC50  
(nM) 
Kiapp 
 (µM) 
k2/K  
(M-1 s-1) 
koff  
(s-1) 
t1/2  
(min) 
VAB 35 
(0.025)* 
8.5 
(1.1) 
6.7 x 102 
(0.2 x 102) 
0.00016  
(1.5 x 10-5) 
72 
TAN 37 
(0.031)* 
1.3 
(0.36) 
1.0 x 104 
(0.09 x 104) 
3.4 x 10-10 
(5.5 x 10-11) 
3.4 x 
107 
Standard errors are in parentheses; *Standard error of logIC50. 
VAB: vaborbactam; TAN: taniborbactam 
 
Importantly, the taniborbactam off-rate was extremely slow and 
difficult to measure, with a half-life (t1/2) indicative of near 
irreversible covalent complex formation (Figure S1). By contrast, 
vaborbactam (Figure S1) exhibited a slow but measurable off rate 
(0.00016 s-1) and a t1/2 of 72 minutes. These data indicate that 
taniborbactam likely forms a more stable complex with KPC-2, and 
is a more effective inhibitor than vaborbactam, at least against 
purified, recombinant enzyme. Values obtained for vaborbactam 
are comparable to those we recently reported for the DBO 
relebactam (calculated in the same way) which exhibits similar Kiapp 
(1.2 μM) and koff values (0.00087 s-1).22 We also note that a slow but 
measurable off-rate has recently been observed for inhibition of 
KPC-2 by non-cyclic phenylboronic acid derivates, with kinetics for 
these compounds appearing to more closely resemble those of 
vaborbactam than taniborbactam.12  
Although both vaborbactam and bicyclic boronates potentiate 
β-lactam activity against KPC-2 producing K. pneumoniae,21, 23 direct 
comparison of their activity is not possible with available data as the 
two have not to date been tested against the same strain. 
Accordingly, their combinations with partner β-lactams cefepime or 
meropenem (β-lactams used clinically, or in trials, in combination 
with taniborbactam or vaborbactam, respectively) were evaluated 
against K. pneumoniae Ecl8 expressing KPC-2. Despite the clear 
improvement in potency of taniborbactam in kinetic experiments, 
both inhibitors have comparable effects upon this KPC-2 producing 
strain (Table S1). The addition of 4 µg/ml inhibitor (the same 
concentration as used for previous taniborbactam MIC 
determinations24, 25) significantly reduced MICs from ≥256 µg/ml 
(cefepime alone) or ≥16 µg/ml (meropenem alone) to ≤0.125 µg/ml, 
a value well below the clinical breakpoints for susceptibility to these 
agents (≤ 2 µg/ml and ≤ 1 µg/ml for cefepime and meropenem 
respectively). Both inhibitors therefore remain viable and potent 
options for potentiating either cefepime or meropenem activity 
against KPC-2 producing K. pneumoniae. 
 
 Crystal Structures 
To further understand their mechanisms of inhibition we 
obtained X-ray crystal structures of KPC-2 complexes with both 
vaborbactam and taniborbactam, at resolutions of 1.2 Å and 0.99 Å,  
respectively (Table S2). In both structures, clear Fo-Fc density in the 
active site reveals that the cyclic boronates inhibit KPC-2 through 
formation of a covalent attachment to the catalytic Ser70 (Figures 
2A and 2B). As previously identified by crystallography of cyclic 
boronate complexes with SBLs and MBLs,19-21, 23, 26, 27 the boron 
atom is sp3 hybridized, i.e. in a tetrahedral geometry, thereby 
mimicking the tetrahedral intermediate formed during β-lactam 
acylation of SBLs. 
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Figure 2. Views from crystal structures of cyclic boronate binding to KPC-2. 
Fo - Fc density calculated in the absence of ligand is shown as a green mesh, 
contoured to 3σ, for (A) vaborbactam (grey sticks) and (B) taniborbactam 
(yellow sticks). (C) Comparison of taniborbactam and vaborbactam in the 
KPC-2 active site. (D) An overlay of vaborbactam and taniborbactam KPC-2 
structures (interactions shown as black and yellow dashes for vaborbactam 
and taniborbactam, respectively).  
 
Both inhibitors were modelled as dual occupancy due to the 
presence of more than one conformation of their respective C-3 
substituents (Figure S2). With vaborbactam, this is evident as a 180° 
rotation of the thiophene moiety, as was also observed on binding 
of vaborbactam to CTX-M-15 (a class A SBL) and AmpC (a class C 
SBL).23 With taniborbactam, the cyclohexane ring adopts two 
orientations, rotated by approximately 65°, with this flexibility also 
highlighted by the fact that the ethylamino ring substituent could 
not be modelled in the final structure due to poorly defined electron 
density. The same atoms could not be modelled in our previously 
reported crystal structure of taniborbactam bound to NDM-1,21 an 
MBL that, like KPC-2, also hydrolyses carbapenems. This contrasts 
with our previously determined X-ray crystal structure of 
taniborbactam bound to OXA-10, an enzyme which is unable to 
hydrolyse carbapenems, in which these atoms were well defined by 
the electron density.21 Flexibility in the taniborbactam C-3  
substituent may therefore solely present when the inhibitor is 
bound to carbapenemases such as NDM-1 and KPC-2. 
The binding modes of vaborbactam and taniborbactam to KPC-2 
are similar; both adopt comparable geometries (Figure 2C) and form 
almost identical interactions with the protein main chain (Figure 2D, 
S3 and Table S3). The inhibitor C6 carboxylates interact with the side 
chains of Thr235, Thr237 and Ser130; their acetamido oxygen with 
the N atom of the Asn132 side chain; and the amino N atoms with 
the backbone oxygen of Thr237. The boron-bound OH groups 
interact with the backbone amides of Thr237 and Ser70 that form 
the oxyanion hole, as well as with a water molecule in the 
deacylating position (DW), albeit with a (0.23 Å) decrease and (0.35 
Å) increase in the distances to Thr237 and DW, respectively, for 
taniborbactam compared to vaborbactam (Table S3). A slight 
movement (1.1 Å) of the indole side chain of Trp105 between the 
vaborbactam and taniborbactam structures reflects the additional 
hydrophobic interactions this residue makes with the bicyclic, and 
not monocyclic, core. Notably, Trp105 is modelled in a single 
conformation in both the vaborbactam and taniborbactam 
structures (Figure 2D). Interactions of KPC-2 Trp105 with β-lactams 
are suggested to be essential for hydrolysis28, and KPC-2 Trp105 is 
indeed stabilised by binding of the β-lactam substrates cefotaxime 
and faropenem (as observed crystallographically29). Conversely, 
however, we have previously observed flexibility of Trp105 (as 
modelled in multiple conformations) in complexes with the DBO 
inhibitor relebactam.22 There is also a difference in the positioning 
of the endocyclic boronate ester oxygen for the two cyclic 
boronates, which may reflect the hybridisation of the adjacent 
carbon as either sp3 (vaborbactam) or sp2 (taniborbactam). This 
results in this oxygen being positioned to either hydrogen bond with 
Thr237 (vaborbactam) or one of the two conformations of Ser130 
(taniborbactam) (Figure 2D and Figure S3).  
The structures reported here represent the first for any cyclic 
boronates bound to carbapenem-hydrolysing SBLs. In Figure 3 we 
therefore compared them with previously determined crystal 
structures for cyclic boronates bound to the extended spectrum 
(class A) SBLs CTX-M-1520, 23 and S. maltophilia L2,26 the class C SBL 
AmpC23, 27 and the class D SBL OXA-10.21 The vaborbactam core 
binds KPC-2 almost identically to CTX-M-15,23 both differing from 
AmpC binding where, unusually, the six-membered cyclic boronic 
acid ester ring is inverted (i.e. the axial/equatorial conformations of 
the C-6 carboxymethyl and C-3 amide substituent are switched), 
resulting in a significantly different binding mode (Figure 3A).23 
Surprisingly, however, the vaborbactam C-3 substituent adopts a 
different conformation in KPC-2 compared to both CTX-M-15 and 
AmpC. In KPC-2, the vaborbactam side-chain is ‘U-shaped’, with the 
C-3 group folded over in a conformation we noted previously as a 
specific feature of bicyclic boronate binding to SBLs.21  
 
 
Figure 3. Cyclic boronate binding across serine-β-lactamases. (A) Overlays 
of vaborbactam binding to KPC-2 (yellow), CTX-M-15 (PDB 4XUZ, pink) and 
AmpC (PDB 4XUX, blue). Arrows indicate the ‘U’ and ‘Z’-shaped 
conformations vaborbactam adopts in KPC-2 and CTX-M-15, respectively. The 
‘straighter’ conformation in AmpC is represented by a blue arrow. (B)  
Overlays of bicyclic boronate binding to KPC-2, CTX-M-15 (PDB 5T66), AmpC 
(PDB 6I30), OXA-10 (PDB 6RTN, orange) and L2 (PDB 5NE1, grey). 
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This contrasts with vaborbactam binding to CTX-M-15, where an 
alternative ‘Z-shaped’ conformation was observed (Figure 3A) in a 
geometry we have previously seen adopted by bicyclic boronates 
when bound to MBLs.20, 21 Indeed, taniborbactam also adopts the 
‘U-shaped’ conformation (Figure 3B), with its overall geometry 
closely reflecting that of other bicyclic boronates bound to CTX-M-
15 (bicyclic boronate 1), L2 (bicyclic boronate 2), OXA-10 
(taniborbactam) and AmpC (bicyclic boronate 1). Importantly, the 
currently available crystal structures indicate none of the bicyclic 
boronates to adopt the ‘Z-shaped’ conformation in SBLs (Figure 3B).  
In contrast to bicyclic boronates, which have a conserved 
binding mode across different SBLs, vaborbactam adopts a greater 
range of conformations in reported SBL complexes. This may be 
reflected in its substantially poorer spectrum of SBL inhibition when 
compared to taniborbactam. Against β-lactamases tested to date, 
vaborbactam has significantly higher IC50s than taniborbactam 
against TEM-116, AmpC and OXA-10/4821 enzymes.  
These crystal structures also provide insights into the significant off-
rate differences we observe between vaborbactam and 
taniborbactam. Release of intact cyclic boronate from KPC-2 would 
be expected to involve Ser70 protonation and cleavage of the O – B 
bond, accompanied by the boron atom switching from tetrahedral 
(sp3) to trigonal (sp2) geometry. Importantly, the positions of Ser70, 
and its interactions with putative proton donors 
(Lys73/‘deacylating’ water) are near-identical in the two complexes. 
Therefore, other factors, such as the environment and positioning 
of the endocyclic oxygen, which differs in our vaborbactam and 
taniborbactam structures, may affect inhibitor release. The 
presence of the adjacent aromatic ring in taniborbactam may also 
reduce negative charge around the boron atom, disfavouring O – B 
cleavage. Alternatively, sp2 hybridisation of the adjacent (aromatic) 
carbon in taniborbactam, compared to the sp3 C6 atom of 
vaborbactam, may constrain this oxygen and prevent any 
repositioning required as the geometry about the boron atom 
rearranges. In addition, the ability of vaborbactam to switch 
between axial/equatorial conformations,23 when compared with 
the rigid bicyclic rings of taniborbactam, may contribute to a faster 
off-rate. Further study will be required to establish the relative 
importance of these, and other, possibilities. 
Experimental 
Enzyme kinetics 
All enzyme assays were performed at 25 °C in 10 mM HEPES (pH 
7.5) and 150 mM NaCl with nitrocefin as a reporter substrate30 (Δε 
486 nm= 20,500 M−1 cm−1) and absorbances read within Greiner half 
area 96-well plates in a POLARstar Omega (BMG LabTech) plate 
reader. Vaborbactam (MedChemExpress) and taniborbactam 
(synthesised as previously described21) were dissolved to 100 mM 
in dimethyl sulfoxide (DMSO) and diluted to the desired 
concentrations in 10 mM HEPES (pH 7.5) and 150 mM NaCl.  
IC50, k2/K, Kiapp and Koff values were calculated using methods 
and equations as previously described.22 Briefly, IC50 values were 
determined by following the initial rates of nitrocefin hydrolysis 
(50 μM) measured after 10-minute preincubation of cyclic boronate 
and KPC-2. A 10-min preincubation time was chosen based on our 
previous data that indicates there is little effect on the inhibition of 
class A β-lactamases by bicylic boronates at longer incubation 
periods.20 Direct competition assays with a range of concentrations 
of cyclic boronate and 50 μM nitrocefin were performed to 
determine both k2/K and Kiapp, reactions were initiated by addition 
of 1 nM KPC-2. For koff calculations, 1 μM KPC-2 was pre-incubated 
with 8 μM cyclic boronate for 30 minutes at room temperature. 
Mixtures were subsequently serially diluted using the jump-dilution 
method31 and reaction monitored following addition of 50 μM 
nitrocefin, the final concentration of KPC-2 was 500 pM.  
 
Minimal inhibitory concentration determination 
The pUBYT vector containing blaKPC-2 under the ISKpn7 
promotor was constructed as previously described.22 MIC values 
were determined using broth microdilution, in triplicate, in cation-
adjusted Mueller-Hinton broth (Sigma) according to the Clinical and 
Laboratory Standards Institute (CLSI) guidelines. Experiments were 
performed in microtiter plates (Corning) containing medium with 
cefepime or meropenem with 4 mg liter−1 inhibitor (vaborbactam or 
taniborbactam diluted from 100 mM stock dissolved in DMSO). 
Plates were incubated overnight at 37°C for 18 to 24 hours, and the 
absorbance at 600 nm was read using a POLARstar Omega (BMG 
LabTech) plate reader. 
 
Crystallisation and structure determination  
Recombinant KPC-2 was produced, purified and crystallised as 
previously described22. To obtain ligand bound structures, crystals 
were soaked in mother liquor supplemented with 1 mM 
vaborbactam or 1 mM taniborbactam for 3 or 16 hours, 
respectively. Crystals were flash-frozen in liquid nitrogen after brief 
exposure to mother liquor containing 30% glycerol. Diffraction data 
were collected at the European Synchrotron Radiation Facility 
(Grenoble, France) on beamline ID23-1 (vaborbactam soak) or ALBA 
(Barcelona, Spain) on beamline BL13-XALOC (taniborbactam soak). 
Data were integrated with DIALS32 (vaborbactam) or XDS33 
(taniborbactam) and scaled in Aimless34. Phases were calculated by 
molecular replacement in Phaser35 using PDB ID 6QW922 (with 
ligands removed) as the starting model. Structures were completed 
with iterative rounds of manual model building in WinCoot36 and 
refinement in Phenix37. The final models contained residues 23-294, 
with their overall structures closely resembling each other (root 
mean square deviation [RMSD]=0.16 Å, over 270 Cα) and native KPC-
2 (PDB ID 5UL829, RMSD=0.14 Å/0.17 Å over 270 Cα). Geometry 
restraints for ligands were calculated using eLBOW in Phenix37. 
Figures were generated in PyMOL38. 
Conclusions 
The results show both cyclic boronates to act as KPC-2 inhibitors, 
potentiating antibiotic activity against laboratory producer strains. 
However, taniborbactam appears more potent against isolated KPC-
2, exhibiting significantly faster inactivation rates, and off-rates 
suggesting near irreversible inhibition. This finding arises from 
direct comparison of cyclic boronate inhibition kinetics under 
identical conditions and highlights the importance of using 
consistent methods for detailed comparisons across multiple β-
lactamases and classes. In addition to the apparent capability of 
bicyclic boronates to act as more versatile cross-class SBL and MBL 
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inhibitors, this greater potency will be an important consideration 
in the clinic, particularly against the most difficult to treat Gram-
negative pathogens. Given the growing incidence of K. pneumoniae 
(and other Gram-negative) strains that co-produce KPC-2 alongside 
MBLs such as NDM-1,39 a taniborbactam combination would be 
expected to represent a more effective treatment option in these 
cases.  
Our crystal structures reveal the boron-containing cyclic cores 
of the two inhibitors, together with the associated carboxylate 
groups, to bind almost identically to KPC-2. The ability of the 
enzyme to accommodate the substantially different substituent 
groups, along with structural comparisons of SBL binding modes for 
mono- and bicyclic compounds, indicates that there may be 
significant scope for development of further iterations of the cyclic 
boronate scaffold that retain the ability to act as potent β-lactamase 
inhibitors. This approach is already bearing fruit for DBOs, with 
iterations now in development that expand the activity profile and 
potency. 5, 22 The need to improve inhibitor activity is becoming 
increasingly important as enzymes such as KPC-2 accumulate 
mutations that provide resistance to clinical inhibitors such as 
avibactam.10 Cyclic boronates represent a potent and versatile β-
lactamase inhibitor scaffold to counter the clinical threat and 
evolution of β-lactamase mediated antibiotic resistance. 
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